Analysis of cytokines in tear fluid from atopic dermatitis patients with dupilumab-associated ocular adverse events

Although the introduction of dupilumab has revolutionized the management of atopic dermatitis (AD), dupilumab-associated ocular adverse events (DAOAE) represent the first cause for discontinuation of dupilumab. The exact pathogenesis of DAOAE events observed is unknown. We conducted a prospective study from October 2019 to June 2020 to determine the feasibility of cytokine analysis in tear fluid obtained by non-invasive capillarity from AD patients treated with dupilumab and to compare the inflammatory cytokine profiles before and during dupilumab treatment between patients with and without DAOAE.